Expertise in
4
conditions

Lin X. Zhong

No.1 Minde Road, 
Nanchang, CN 
Expertise in
4
conditions
No.1 Minde Road, 
Nanchang, CN 
OverviewLocationsClinical Research

Overview

Lin Zhong practices in Nanchang, China. Zhong is highly rated in 4 conditions, according to our data. Their top areas of expertise are Cerebral Hypoxia, Hemangioma, Liver Cancer, Liver Transplant, and Endoscopy.

Their clinical research consists of co-authoring 396 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No.1 Minde Road, Nanchang, China
Other Locations
358 Datong Road, Datong, 200137, China
No. 308 Ningxia Road, Qingdao, 266071, China
No. 222 Zhongshan Road, Dalian, China
No. 20 East Yuhuangding Road, Yantai, 264000, China
100 Haining Road, Shanghai, 200080, China
278 Middle Section Of Baoguang Avenue, Chengdu, 610500, China
222 Zhongshan Road, Dalian, 116011, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
Study Drug: Pamiparib
Study Phase: Phase 3
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Phase: Phase 3
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Syndrome
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Syndrome
Enrollment Status: Completed
Publish Date: April 21, 2022
Intervention Type: Drug
Study Drugs: Sirolimus, Prednisolone
Study Phase: Phase 2
Efficacy and Safety of Sirolimus in the Treatment of the Complicated Vascular Anomalies
Efficacy and Safety of Sirolimus in the Treatment of the Complicated Vascular Anomalies
Enrollment Status: Completed
Publish Date: March 15, 2022
Intervention Type: Drug
Study Phase: Not Applicable
View 3 Less Clinical Trials

396 Total Publications

Correction: The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.
Correction: The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.
Journal: Journal of cardiovascular translational research
Published: November 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhong's expertise for a condition
ConditionClose
      View All 94 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile